Occult hepatitis B infection in egyptian chronic hepatitis C patients: Prevalence, impact on pegylated interferon/ribavirin therapy

Virology Journal

Volumn 7, Issue , 2010, Pages

  Emara, Mohamed H ^a   El Gammal, Nahla E ^a   Mohamed, Lamiaa A ^b   Bahgat, Maged M ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

^b Zagazig University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS DNA; ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; MACROGOL DERIVATIVE;

ADULT; AGE DISTRIBUTION; ARTICLE; DRUG RESPONSE; EGYPT; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PARAMETER; PREVALENCE; VIRUS LOAD; BLOOD; COMORBIDITY; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ADULT; AGE DISTRIBUTION; COMORBIDITY; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREVALENCE; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 78349276985     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-324     Document Type: Article

References (38)

1. Nonresponse to treatment for hepatitis C: current management strategies. H Yuan W Lee, Drugs 2008 68 27 42 10.2165/00003495-200868010-00003 18081371
2. Epidemiology of HCV in Egypt. M Mohamed, The Afro-Arab Liver journal 2004 3 41 52
3. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. SJ Hadziyannis HJ Sette TR Morgan V Balan M Diago P Marcellin G Ramadori H Bodenheimer D Bernstein M Rizzetto S Zeuzem PJ Pockros A Lin AM Ackrill PEGASYS International Study Group, Ann Intern Med 2004 140 346 355 14996676
4. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. M Derbala A Amer A Bener AC Lopez M Omar M El Ghannam, J Viral Hepat 2005 12 380 385 10.1111/j.1365-2893.2005.00604.x 15985008
5. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? C Brechot V Thiers D Kremsdorf B Nalpas S Pol P Paterlini-Brechot, Hepatol 2001 34 194 203 10.1053/jhep.2001.25172 (Pubitemid 32591500)
6. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. I Cacciola T Pollicino G Squadrito G Cerenzia M Orlando G Raimondo, N Engl J Med 1999 341 22 6 10.1056/NEJM199907013410104 10387938
7. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. I Cacciola T Pollicino G Squadrito G Cerenzia D Villari R de Franchis T Santantonio S Brancatelli G Colucci G Raimondo, Hepatol 2000 31 507 512 10.1002/hep.510310235
8. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection. R Kannangai P Vivekanandan D Netski S Mehta G Kirk D Thomasb M Torbenson, J Clinical Virol 2007 39 101 105 10.1016/j.jcv.2007.03.006 (Pubitemid 46777424)
9. The impact of previous HBV infection on the course of chronic hepatitis C. N De Maria A Colantoni L Friedlander G Leandro R Idilman J Harig D Van Thiel, Am J Gastroenterol 2000 95 3529 3536 10.1016/S0002-9270(00)02164-X 11151889
10. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection. A Zignego R Fontana S Puliti M Monti G Careccia F Giannelli C Giannini G Buzzelli MR Brunetto F Bonino P Gentilini, Arch Virol 1997 142 535 544 10.1007/s007050050099 9349299 (Pubitemid 27161773)
11. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. R Fukuda N Ishimura M Niigaki S Hamamoto S Satoh S Tanaka Y Kushiyama Y Uchida S Ihihara S Akagi M Watanabe Y Kinoshita, J Med Virol 1999 58 201 207 10.1002/(SICI)1096-9071(199907)58:3<201::AID-JMV33.0.CO;2-2 10447413
12. Co-infection by serologically silent hepatitis B virus may contribute to poor interferon response in patients with chronic hepatitis C by down-regulation of type-I interferon receptor gene expression in the liver. R Fukuda N Ishimura S Hamamoto M Moritani Y Uchida S Ishihara S Akagi M Watanabe Y Kinoshita, J Med Virol 2001 63 220 227 10.1002/1096-9071(200103)63:3<220::AID-JMV10043.0. CO;2-3 11170061
13. The clinical features of chronic hepatitis C are not affected by the coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. K Nirei M Kaneko M Moriyama Y Arakawa, Intervirology 2000 43 95 101 10.1159/000025030 10971127
14. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. J Sheu G Huang L Shih, Gastroenterology 1992 103 1322 1327 1327934
15. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: A study of a low endemic area. P Paterlini F Driss B Nalpas E Pisi D Franco P Berthelot C Brechot, Hepatology 1993 17 20 29 10.1002/hep.1840170106 8380790
16. Statements from the Taormina expert meeting on occult hepatitis B virus infection. G Raimondo JP Allain MR Brunetto MA Buendia DS Chen M Colombo A Crax F Donato C Ferrari GB Gaeta WH Gerlich M Levrero S Locarnini T Michalak MU Mondelli JM Pawlotsky T Pollicino D Prati M Puoti D Samuel D Shouval A Smedile G Squadrito C Trépo E Villa H Will AR Zanetti F Zoulim, J Hepato 2008 49 625 657 10.1016/j.jhep.2008.07.005
17. An algorithm for grading activity in chronic hepatitis C. P Bedossa T Poynard The French METAVIR Cooperative Study Group, Hepatology 1996 24 289 293 10.1002/hep.510240201 8690394
18. Analysis of HCV co- infection with occult hepatitis B virus in patients undergoing IFN therapy. E Kattab I Chemin I Vuillermoz C Vieux S Mrani O Guillaud C Trepo F Zoulim, J Clin Virol 2005 33 150 157 10.1016/j.jcv.2004.10. 016 15911431
19. Therapeutic Effects of Pegylated Interferon Plus Ribavirin in Chronic Hepatitis C Patients with Occult Hepatitis B Virus Dual infection. LW Chen RN Chien CL Yen JJ Chang CJ Liu CL Lin, J Gastroenterol Hepatol 2010 25 259 263 10.1111/j.1440-1746.2009.06006.x 19817959
20. Prevalenc and Impact of Occult Hepatitis B Infection in Chronic Hepatitis C Patients treated with Pegylated Interferon and Ribavirin. M Levast S Larrat MA Thelu S Nicod A Plages A Cheveau JP Zarski JM Seigneurin P Mornad, J Med Virol 2010 82 747 754 10.1002/jmv.21695 20336715
21. Prevalence of hepatitis B and C in Egypt and Africa. M Attia, Antivir Ther 1998 3 1 9 10726051
22. Occult hepatitis B virus infection. G Raimondo T Pollicino I Cacciola G Squadrito, J Hepatol 2007 46 160 170 10.1016/j.jhep.2006.10.007 17112622
23. Occult hepatitis B virus and hepatitis C virus infections. V Carreno J Bartolome I Castillo J Quiroga, Rev Med Virol 2008 18 139 157 10.1002/rmv.569 18265423
24. Suppression of Hepatitis B Virus Expression and Replication by Hepatitis C Virus Core Protein in HuH-7 Cells. C Shih S Lo T Miyamura S Chen Y Lee, J Virol 1993 67 5823 5832 8396658
25. European Association for the Study of the Liver EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009 50 227 242 10.1016/j.jhep.2008.10.001 19054588
26. Multiple surface antigen mutations in five blood donors with occult hepatitis B virus infection. H Zaaijer P Torres A Ontanon L Ponte M Koppelman P Lelie F van Hemert H Boot, J Med Virol 2008 80 1344 1349 10.1002/jmv.21233 18551607
27. Occult hepatitis B virus and hepatitis C virus infections. V Carreno J Bartolome I Castillo J Quiroga, Rev Med Virol 2008 18 139 157 10.1002/rmv.569 18265423
28. Occult hepatitis B virus infection: A case of reactivation in a patient receiving immunosuppressive treatment for allogeneic bone marrow transplantation. CL Giudice M Martinengo P Pietrasanta L Bocciardo C Malavasi S Rastelli M Faraci G Tripodi, Blood Transfus 2008 6 46 50 18661923
29. Significance of isolated hepatitis C core antibody in blood donors. RB Schifman SL Rivers RE Sampliner JE Krammes, Arch Intern Med 1993 153 2261 2266 10.1001/archinte.153.19.2261 8215729
30. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. N Yuki T Nagaoka M Yamashiro K Mochizuki A Kaneko K Yamamoto M Omura K Hikiji M Kato, Hepatology 2003 37 1172 1179 10.1053/jhep.2003.50171 12717399
31. HCV Genotype and "Silent" HBV coinfection: Two main risk factors for a more severe liver disease. A El-Shaarawy M Abdel Aziz S Abdel Rahman E Rageh A El-Saharnouby, Tanta Medi Sci J 2007 2 15 26
32. Hepatitis C genotyping versus serotyping in Egyptian patients. A Zekri A Bahnassy A Ramadan M El-Bassuoni A Badran MA Madwar, Infection 2001 29 24 36 10.1007/s15010-001-0010-8 11261753
33. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B. J Kato K Hasegawa N Torii K Yamaguchi N Hayashi, Hepatology 1996 23 389 395 10.1002/hep.510230301 8617416
34. Occult hepatitis B virus infection does not affect liver histology orresponse to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. P Fabris D Brown G Tositti L Bozzola MT Giordani P Bevilacqua F de Lalla GJ Webster G Dusheiko, J Clin Virol 2004 29 160 166 10.1016/S1386-6532(03)00117-3 14962784
35. Response of patients with dual hepatitis B virus and C virus infection to interferon therapy. YF Liaw RN Chien SM Lin CT Yeh SL Tsai S Sheen CM Chu, J Interferon Cytokine Res 1997 17 449 452 10.1089/jir.1997.17.449 9282824
36. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. C Hui E Laub H Wu A Montob M Kimb J Lukd G Lau T Wright, J Clin Virol 2006 35 185 192 10.1016/j.jcv.2005.07.003 16103008
37. Dual chronic hepatitis B virus and hepatitis C virus infection. CJ Liu PJ Chen DS Chen, Hepatol Int 2009 3 517 525 http://www.springerlink.com/content/ g8086332052jq5w6/fulltext.html Published online: 8 August 2009. Asian Pacific Association for the Study of the Liver 2009 10.1007/s12072-009-9147-9 19669238
38. Hepatitis B Virus infection: The Egyptian Situation. A El-Zayadi, Arab J Gastroenterol 2007 8 94 98